SG11201707111RA - Transposase polypeptides and uses thereof - Google Patents
Transposase polypeptides and uses thereofInfo
- Publication number
- SG11201707111RA SG11201707111RA SG11201707111RA SG11201707111RA SG11201707111RA SG 11201707111R A SG11201707111R A SG 11201707111RA SG 11201707111R A SG11201707111R A SG 11201707111RA SG 11201707111R A SG11201707111R A SG 11201707111RA SG 11201707111R A SG11201707111R A SG 11201707111RA
- Authority
- SG
- Singapore
- Prior art keywords
- transposase polypeptides
- transposase
- polypeptides
- Prior art date
Links
- 102000008579 Transposases Human genes 0.000 title 1
- 108010020764 Transposases Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562131827P | 2015-03-11 | 2015-03-11 | |
| PCT/US2016/021693 WO2016145146A1 (en) | 2015-03-11 | 2016-03-10 | Transposase polypeptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201707111RA true SG11201707111RA (en) | 2017-09-28 |
Family
ID=55587385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707111RA SG11201707111RA (en) | 2015-03-11 | 2016-03-10 | Transposase polypeptides and uses thereof |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10570382B2 (en) |
| EP (2) | EP3268470B1 (en) |
| JP (3) | JP6775515B2 (en) |
| KR (1) | KR102615825B1 (en) |
| CN (1) | CN107532174A (en) |
| AU (2) | AU2016229094B2 (en) |
| CA (1) | CA2977818A1 (en) |
| DK (1) | DK3268470T3 (en) |
| ES (1) | ES2854675T3 (en) |
| HK (1) | HK1248757A1 (en) |
| HU (1) | HUE053368T2 (en) |
| IL (2) | IL285286B2 (en) |
| MX (2) | MX2017011679A (en) |
| PL (1) | PL3268470T3 (en) |
| RU (2) | RU2020127887A (en) |
| SG (1) | SG11201707111RA (en) |
| WO (1) | WO2016145146A1 (en) |
| ZA (1) | ZA201706420B (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| WO2014186469A2 (en) | 2013-05-14 | 2014-11-20 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| CN106414748B (en) | 2014-02-14 | 2021-05-28 | 得克萨斯州大学系统董事会 | Chimeric antigen receptor and method of preparation |
| ES2806126T3 (en) | 2014-11-05 | 2021-02-16 | Univ Texas | Chimeric antigen receptors (CARs) selectively target protein complexes |
| AU2016222850B2 (en) | 2015-02-24 | 2021-04-01 | Board Of Regents, The University Of Texas System | Selection methods for genetically-modified T cells |
| MX2017011679A (en) | 2015-03-11 | 2018-02-09 | Univ Texas | Transposase polypeptides and uses thereof. |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| CA2997673A1 (en) | 2015-09-15 | 2017-03-23 | Board Of Regents, The University Of Texas System | T-cell receptor (tcr)-binding antibodies and uses thereof |
| EP3368075B1 (en) | 2015-10-27 | 2020-01-29 | Board of Regents, The University of Texas System | Chimeric antigen receptor molecules and uses thereof |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| CA3025667A1 (en) | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
| EP3529347A1 (en) | 2016-10-19 | 2019-08-28 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| IL267865B1 (en) | 2017-01-10 | 2024-03-01 | Intrexon Corp | Modulating expression of polypeptides via new gene switch expression systems |
| EP3673053A1 (en) * | 2017-08-21 | 2020-07-01 | EMBL European Molecular Biology Laboratory | Improved transposase polypeptide and uses thereof |
| EP3725092A4 (en) | 2017-12-14 | 2021-09-22 | FloDesign Sonics, Inc. | Acoustic transducer drive and controller |
| KR20200128703A (en) | 2018-03-06 | 2020-11-16 | 프레시전 인코포레이티드 | Hepatitis B vaccine and uses thereof |
| WO2020168086A1 (en) * | 2019-02-13 | 2020-08-20 | Geerlings Maurits W | Nanocarriers for the delivery of nucleic acids and uses thereof |
| EP4028413A1 (en) | 2019-09-10 | 2022-07-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| WO2022147444A2 (en) | 2020-12-30 | 2022-07-07 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| KR20230150336A (en) | 2021-02-25 | 2023-10-30 | 알로노스 테라퓨틱스 인코포레이티드 | Recombinant vector containing polycistronic expression cassette and method of using same |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US5925545A (en) | 1996-09-09 | 1999-07-20 | Wisconsin Alumni Research Foundation | System for in vitro transposition |
| AU745049B2 (en) | 1997-03-11 | 2002-03-07 | Regents Of The University Of Minnesota | DNA-based transposon system for the introduction of nucleic acid into DNA of a cell |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| EP1232959B1 (en) * | 1999-06-02 | 2004-09-15 | Alcan Technology & Management AG | Child-resistant packaging for tablets |
| AU2003231048A1 (en) | 2002-04-22 | 2003-11-03 | Regents Of The University Of Minnesota | Transposon system and methods of use |
| CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
| US20060026699A1 (en) * | 2004-06-04 | 2006-02-02 | Largaespada David A | Methods and compositions for identification of genomic sequences |
| JP5726522B2 (en) * | 2007-07-04 | 2015-06-03 | マックス−デルブリュック−ツェントルム フューア モレキュラーレ メディツィン | Transposon system-a hyperactive variant of the sleeping beauty transposase protein |
| WO2010008564A2 (en) * | 2008-07-16 | 2010-01-21 | Recombinetics | Plaice dna transposon system |
| JP5897335B2 (en) * | 2009-01-23 | 2016-03-30 | エヌエスジーン・アクティーゼルスカブＮｓＧｅｎｅ Ａ／Ｓ | Improved cell lines and their use in encapsulated cell biodelivery |
| KR20140043340A (en) | 2011-04-13 | 2014-04-09 | 이뮤니쿰 에이비 | Method for priming of t cells |
| US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| EP2904004B1 (en) | 2012-10-04 | 2018-11-21 | Research Development Foundation | Serine protease molecules and therapies |
| WO2014186469A2 (en) * | 2013-05-14 | 2014-11-20 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| AU2014268364A1 (en) | 2013-05-24 | 2015-12-10 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| WO2015061694A2 (en) | 2013-10-25 | 2015-04-30 | Board Of Regents, The University Of Texas System | Polyclonal gamma delta t cells for immunotherapy |
| CN106414748B (en) | 2014-02-14 | 2021-05-28 | 得克萨斯州大学系统董事会 | Chimeric antigen receptor and method of preparation |
| US20170158749A1 (en) | 2014-04-23 | 2017-06-08 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) and methods for making and using the same |
| WO2015164740A1 (en) | 2014-04-24 | 2015-10-29 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| WO2016073755A2 (en) | 2014-11-05 | 2016-05-12 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| ES2806126T3 (en) | 2014-11-05 | 2021-02-16 | Univ Texas | Chimeric antigen receptors (CARs) selectively target protein complexes |
| AU2016222850B2 (en) | 2015-02-24 | 2021-04-01 | Board Of Regents, The University Of Texas System | Selection methods for genetically-modified T cells |
| MX2017011679A (en) * | 2015-03-11 | 2018-02-09 | Univ Texas | Transposase polypeptides and uses thereof. |
| CA2997673A1 (en) | 2015-09-15 | 2017-03-23 | Board Of Regents, The University Of Texas System | T-cell receptor (tcr)-binding antibodies and uses thereof |
| EP3368075B1 (en) | 2015-10-27 | 2020-01-29 | Board of Regents, The University of Texas System | Chimeric antigen receptor molecules and uses thereof |
-
2016
- 2016-03-10 MX MX2017011679A patent/MX2017011679A/en unknown
- 2016-03-10 RU RU2020127887A patent/RU2020127887A/en unknown
- 2016-03-10 DK DK16711096.4T patent/DK3268470T3/en active
- 2016-03-10 HU HUE16711096A patent/HUE053368T2/en unknown
- 2016-03-10 JP JP2017547412A patent/JP6775515B2/en active Active
- 2016-03-10 PL PL16711096T patent/PL3268470T3/en unknown
- 2016-03-10 CA CA2977818A patent/CA2977818A1/en active Pending
- 2016-03-10 ES ES16711096T patent/ES2854675T3/en active Active
- 2016-03-10 WO PCT/US2016/021693 patent/WO2016145146A1/en active Application Filing
- 2016-03-10 SG SG11201707111RA patent/SG11201707111RA/en unknown
- 2016-03-10 US US15/556,868 patent/US10570382B2/en active Active
- 2016-03-10 CN CN201680017179.9A patent/CN107532174A/en active Pending
- 2016-03-10 AU AU2016229094A patent/AU2016229094B2/en active Active
- 2016-03-10 EP EP16711096.4A patent/EP3268470B1/en active Active
- 2016-03-10 KR KR1020177027114A patent/KR102615825B1/en active IP Right Grant
- 2016-03-10 EP EP20204973.0A patent/EP3851523A1/en active Pending
- 2016-03-10 IL IL285286A patent/IL285286B2/en unknown
- 2016-03-10 RU RU2017134741A patent/RU2735700C2/en active
-
2017
- 2017-09-10 IL IL254394A patent/IL254394B/en unknown
- 2017-09-11 MX MX2021014712A patent/MX2021014712A/en unknown
- 2017-09-22 ZA ZA2017/06420A patent/ZA201706420B/en unknown
-
2018
- 2018-06-27 HK HK18108277.7A patent/HK1248757A1/en unknown
-
2020
- 2020-01-14 US US16/742,571 patent/US10883094B2/en active Active
- 2020-04-20 AU AU2020202653A patent/AU2020202653B2/en active Active
- 2020-10-06 JP JP2020168936A patent/JP6970991B2/en active Active
- 2020-11-24 US US17/103,500 patent/US11492604B2/en active Active
-
2021
- 2021-10-25 JP JP2021173757A patent/JP2022025097A/en not_active Withdrawn
-
2022
- 2022-10-26 US US18/049,944 patent/US20230151344A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285286A (en) | Transposase polypeptides and uses thereof | |
| IL275307B (en) | Syntac polypeptides and uses thereof | |
| IL281273A (en) | Modified fgf-21 polypeptides and uses thereof | |
| HK1247122A1 (en) | Combinations and uses thereof | |
| IL254241A0 (en) | Etv2 and uses thereof | |
| GB201410031D0 (en) | Polypeptides and uses thereof | |
| GB201517786D0 (en) | Methods and materials | |
| HK1246288A1 (en) | S1pr2 antagonists and uses therefor | |
| SG11201610918RA (en) | Peptides and uses thereof | |
| GB201613143D0 (en) | Polypeptides and uses thereof | |
| GB201613142D0 (en) | Polypeptides and uses thereof | |
| GB201617925D0 (en) | Proteins and uses | |
| RS62066B1 (en) | Modified fgf-21 polypeptides and uses thereof |